29/02/2024 - 15:02

First pancreatic cancer patient dosed in Radiopharm study

29/02/2024 - 15:02


Upgrade your subscription to use this feature.

Radiopharm Theranostics says it has dosed its first pancreatic cancer patient in the initial phase of a study aimed at providing doctors with an enhanced screening process for the lethal and aggressive disease. The clinical trial is for the company’s patented “RAD301” radiopharmaceutical technology that is designed to detect lesions in patients with pancreatic ductal adenocarcinoma and create better health outcomes.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options